The Digital Object Identifier plays a central role in this system. A DOI is a persistent alphanumeric string assigned to a scholarly work that resolves to a stable landing page, regardless of where the content is hosted or how the surrounding website changes over time. Because the Article in Press receives its DOI at the moment of acceptance, any citation made to the early version will continue to resolve correctly after the final Version of Record replaces it, since the DOI is retained across the transition. This design decision reflects a broader shift in scholarly publishing toward treating the accepted manuscript as a citable scientific contribution in its own right, rather than as a preliminary draft that must remain hidden until production is complete. For researchers who build on new findings quickly, particularly in fast-moving fields such as pharmacology and toxicology where timely access to dose-response data, safety signals, and mechanistic results can influence ongoing studies, the interval between acceptance and final publication can be scientifically meaningful.

Readers should nonetheless understand what the Article in Press label signals about the maturity of the text. Errors affecting the content may be discovered during the final production process, and corrections identified at this stage are incorporated during author proofing, the step in which authors review the typeset version of their manuscript and mark any necessary changes. The Version of Record that ultimately replaces the Article in Press is the definitive, fully produced article, and it is the version against which future corrections, retractions, or editorial expressions of concern would formally be logged. The early-access version is clearly labelled online to make this distinction visible, which helps readers, indexers, and citation databases avoid confusion about which iteration of a paper they are consulting. All legal disclaimers that apply to the journal also apply to Articles in Press, meaning that the same standards governing the final article govern the early version as well.

This publication model is closely tied to the open access movement. Fully open access journals make every accepted manuscript available at the Article in Press stage, ensuring that no paywall or production delay separates the scientific community from peer-reviewed findings once acceptance has occurred. The economics of open access publishing, in which article processing charges or institutional agreements cover the costs of publication rather than subscription fees, make this rapid-release model feasible: because revenue does not depend on controlling access to the finished product, there is no commercial reason to withhold accepted work. For pharmacology and toxicology specifically, this can matter in practical terms. Findings concerning drug safety, toxicological mechanisms, adverse effect profiles, and therapeutic interactions are often of immediate interest to clinicians, regulators, and other researchers, and narrowing the window between acceptance and visibility serves those audiences directly.

The specific article at issue here appears in the Articles in Press feed of BMC Pharmacology and Toxicology, a peer-reviewed journal that publishes research spanning the pharmacological and toxicological sciences. Work in this field commonly addresses how chemical compounds interact with biological systems at the level of molecular targets, cellular pathways, whole organisms, and populations. Studies may range from preclinical investigations of drug mechanisms and toxicity pathways to evaluations of therapeutic outcomes and safety pharmacology. The journal’s scope reflects the substantial overlap between pharmacology and toxicology as disciplines: a compound’s therapeutic window is defined by the relationship between the doses that produce benefit and the doses that produce harm, and research in either field frequently informs the other. Readers consulting the Articles in Press feed should therefore expect a steady stream of newly accepted manuscripts covering this breadth, each carrying the caveats described above about its provisional editorial status.

One practical consequence of the Article in Press model concerns how such manuscripts should be cited. Because the DOI is assigned at acceptance and persists through the transition to the Version of Record, citations made to the early version remain valid indefinitely. However, the content of the final published version may differ in small ways from the Article in Press, since author proofing can correct typographical errors, clarify ambiguous passages, and fix substantive mistakes discovered during production. Scholars who rely heavily on a particular early-access manuscript, for example by reproducing a specific numerical result or quoting a methodological detail, may wish to verify those details against the final Version of Record once it appears. Most modern reference managers and publisher platforms handle this transition automatically, updating citation records when the final version is published, but individual vigilance remains worthwhile for claims that carry particular weight in downstream work.

The existence of an Articles in Press feed also illustrates how journals communicate their editorial pipeline to the public. By maintaining a continuously updated list of accepted manuscripts, the journal signals both its throughput and its transparency: readers can see that peer review has concluded and that the work has met the journal’s bar for acceptance, even before the polished final article is available. This visibility can be particularly valuable for systematic reviewers and meta-analysts, who are often advised to search for articles in press and early-access material to reduce publication bias and to capture the most current evidence. It can also benefit the authors themselves, whose accepted work becomes visible and citable months earlier than would otherwise be possible, a factor that can matter for grant reporting, thesis completion, and career progression.

Press releases represent another area where the Article in Press stage has practical implications. Journals that support press outreach for accepted manuscripts typically ask authors and institutions to coordinate with the production editor as early as possible, because embargoes, timing, and the availability of the citable version all need to be aligned. A press release issued before the Article in Press is live risks directing journalists to a manuscript that cannot yet be accessed or cited, while a release issued after the final Version of Record appears may miss the window of peak news interest. Coordinating early allows the journal, the authors, and institutional communications offices to synchronize the release of the story with the moment the citable early version becomes publicly available, maximizing both accuracy and impact.

For readers evaluating any Article in Press, a few habits of critical appraisal remain as important as they are for final published articles. Peer review, however rigorous, is a process of expert scrutiny rather than a guarantee of truth, and the replication crisis documented across the biomedical sciences has underscored the value of independent confirmation, transparent data, and careful attention to statistical methods. Early-access status adds one more layer of provisional character: the text may still be refined, and any errors identified during production will be corrected in the final version. Readers should therefore treat the Article in Press as a legitimate, citable scientific contribution while remaining aware that the definitive Version of Record is the version against which the scholarly record will ultimately be judged. Checking the journal’s labeling, noting the DOI, and revisiting the article after final publication are simple practices that keep one’s citations accurate and one’s understanding of the evidence current.

Finally, the mechanics described here reflect broader trends in scholarly communication that extend well beyond a single journal. The movement toward continuous publication, in which articles appear online as soon as they are ready rather than being gathered into discrete issues, has blurred the traditional boundaries of the journal volume and made early access the norm rather than the exception at many publishers. Persistent identifiers such as the DOI, alongside ORCID identifiers for authors and increasingly granular metadata standards, underpin this ecosystem by ensuring that each version of a work can be located, linked, and cited unambiguously. For the pharmacology and toxicology community, whose findings feed directly into drug development, regulatory assessment, and clinical practice, the ability to access and cite peer-reviewed work at the moment of acceptance, with the assurance that the citation will remain stable through to the final Version of Record, represents a meaningful improvement in how scientific knowledge circulates. The Articles in Press mechanism, with its clear labeling, retained DOI, and defined correction pathway, is a small but consequential piece of that larger infrastructure, and understanding how it works helps readers navigate the modern scientific literature with appropriate confidence and appropriate caution.

Subject of Research: Early-access publishing workflow for peer-reviewed articles

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, peer review, open access, digital object identifier, version of record, scientific publishing, Springer Nature, BMC Pharmacology and Toxicology, author proofing, scholarly communication, Articles, Press

The mechanics behind the Article in Press model reveal how deeply digital infrastructure has reshaped the economics and tempo of scholarly publishing. In the traditional print-era workflow, a paper accepted by a journal would wait in a queue for an issue to be assembled, typeset, printed, and distributed, a process that could consume several months. The early-access approach decouples acceptance from publication. The accepted, peer-reviewed manuscript is posted as submitted or lightly processed, clearly labelled online to show that it is not the final Version of Record. Because the DOI is assigned at this stage, citations accumulate from the moment the paper becomes visible, and the citation record carries forward seamlessly: when the final Version of Record is published, it replaces the Article in Press under the same DOI, so no reference ever breaks.

That permanence of the identifier is more than a technical convenience. It solves a problem that plagued early experiments with online-first publishing in the late 1990s and 2000s, when preliminary web versions sometimes carried different identifiers or no identifiers at all, fragmenting the citation trail. Under the current model, the DOI acts as a stable thread running through every stage of a paper’s life. A researcher who cites the Article in Press version today is citing the same object that will exist as the Version of Record tomorrow. This continuity matters for meta-analyses, systematic reviews, and clinical guidelines, all of which depend on citation records that remain coherent over decades.

The system is not without caveats, and the journals that use it are explicit about them. An Article in Press may be subject to further editing, because errors affecting the content can be discovered during the final production process. Errors in the early-access version are corrected during the author proofing stages of production, and those corrections are reflected in the final Version of Record. In practice, this means the version a reader encounters online immediately after acceptance is a snapshot of the peer-reviewed manuscript, not a polished, typeset artifact. Figures may be reformatted, references may be rechecked, and copyediting may adjust phrasing. The scientific substance has passed peer review, but the presentation is still in transit.

For readers, the labelling is the critical safeguard. Every Article in Press is clearly marked online to indicate that it is not the final Version of Record, and all legal disclaimers relating to the journal apply to it. This transparency matters most in fast-moving or high-stakes fields. In pharmacology and toxicology, where a single paper on a drug’s toxicity profile can be picked up by clinicians, journalists, and regulators within hours of appearing online, the distinction between a peer-reviewed but not-yet-final manuscript and a fully published Version of Record is a meaningful one. The labelling system exists precisely so that downstream users can weigh the evidence appropriately, understanding that the peer-review filter has already been applied even though production remains incomplete.

The open-access dimension adds another layer of significance. Fully open-access journals provide this early-access service on every accepted manuscript, meaning that no accepted paper waits behind a production queue before becoming publicly visible. This has a democratizing effect on the speed of science. A researcher in a low-resource setting, a clinician in a community hospital, or a journalist covering a public health story can all access the accepted findings at the same moment as researchers at elite institutions. The traditional lag between acceptance and publication, which once created an information asymmetry favoring those with library access to the fastest journals, is effectively eliminated at the moment of acceptance.

Behind the scenes, the workflow that makes this possible involves a coordinated sequence of editorial and production steps. Once peer review concludes and the editors issue a formal acceptance, the manuscript enters the production pipeline. The Article in Press version is generated from the accepted files, assigned its DOI, and posted to the journal’s online platform. Author proofing then begins, in which the authors review the typeset version and flag errors. Corrections discovered at this stage are folded into the Version of Record. The process acknowledges a simple truth about scholarly publishing: even after peer review, the transformation of a manuscript into a finished published article involves human steps that can introduce or reveal errors, and the early-access model builds in a visible, correctable intermediate state rather than pretending the first online appearance is flawless.

For authors, the practical implications are significant. An accepted paper begins accruing citations, visibility, and potential media attention immediately, which can matter for grant applications, tenure timelines, and career progression. But authors also carry a responsibility during the proofing stage, because errors they fail to catch will persist into the Version of Record. Journals that use the Article in Press model typically encourage authors organizing press releases to contact their production editor as early as possible, ensuring that media coverage aligns with the availability and status of the paper. The coordination between publicity and publication status is a small but telling detail: it reflects an awareness that early-access papers enter the public sphere before they are finalized, and that communication about them should reflect that status honestly.

The broader significance of the Article in Press model lies in what it reveals about the changing tempo of science itself. Research in areas such as infectious disease, toxicology, and pharmacology increasingly unfolds on timelines measured in weeks, not years, and the publishing ecosystem has adapted accordingly. The early-access approach preserves the essential checkpoints of peer review and formal publication while removing the artificial delay between them. It treats the DOI as the permanent anchor of a paper’s identity and treats the published record as a sequence of improving versions rather than a single fixed event. For readers, the takeaway is straightforward but important: when you encounter a paper labelled as an Article in Press, you are looking at peer-reviewed science that has been accepted and made permanently citable, but not yet finalized. The findings are real and reviewable, the identifier is stable, and the final version will arrive under the same DOI, correcting any residual errors along the way. In an era when the speed of dissemination shapes the pace of discovery, that combination of immediacy and transparency has quietly become one of the most important infrastructures in scientific communication.

Subject of Research: Early-access publishing of accepted peer-reviewed manuscripts as Articles in Press with permanent DOIs

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Article in Press, peer review, DOI, open access, scholarly publishing, Version of Record, pharmacology, toxicology, scientific communication, early access, citation, BMC

The mechanics of the system are deceptively simple. Acceptance, not typesetting, is the moment a paper earns its place in the literature. Under traditional workflows, a manuscript that survived peer review could then wait in a production queue while copy editors reformatted references, adjusted figures to print specifications and compiled the final issue. That delay, sometimes stretching to several months, meant that clinically relevant findings — including studies relevant to the care of older adults, the core remit of a geriatrics journal — were locked away from the researchers and clinicians who needed them. The Article in Press model removes that bottleneck by publishing the accepted manuscript in near-real time, with the DOI acting as the permanent handle that follows the paper through every subsequent version.

The Digital Object Identifier is the linchpin of the entire arrangement. A DOI is a persistent alphanumeric string, resolved through the DOI system to a stable landing page, which means that citations built on an Article in Press remain valid even after the final version replaces the early one. When the final Version of Record is eventually published, it takes the place of the Article in Press while retaining the same DOI. In practical terms, a citation issued the day the paper first appeared online still points to the correct paper a year later, after corrections have been made and the typeset article has been released. This permanence is what allows journals to encourage immediate citation of early-access work without fear of broken links or orphaned references.

That does not mean an Article in Press is a finished product, and publishers are careful to say so. Every such article is clearly labelled online to show that it is not the final Version of Record, and all of the journal’s legal disclaimers apply to it exactly as they would to a published issue. The reason for the labelling is that the early version may still be subject to further editing: errors affecting the content can be discovered during the final production process, and any errors found in an Article in Press will be corrected during the author proofing stages of production. Those corrections are then reflected in the final Version of Record. The workflow acknowledges a basic truth of publishing at scale — that the transformation from an author-supplied accepted manuscript to a fully typeset, paginated article is itself a quality-control step, and that mistakes can surface anywhere along it.

For fully open-access journals, this early-release service is now provided on every accepted manuscript, without exception. That universality matters for equity in science communication. Subscription journals have historically controlled the timing of a paper’s visibility, and delays in production have fallen unevenly across disciplines and institutions. When a journal commits to releasing every accepted paper immediately, an author at a small department gains the same rapid visibility as one at a wealthy research university. In fields such as geriatrics, where findings about falls, dementia care or polypharmacy can influence clinical practice quickly, the difference between publication now and publication in three months is not merely academic.

Early access also reshapes the sociology of citation. Because an Article in Press can be cited from the day it appears, systematic reviews and meta-analyses can incorporate studies that would otherwise have missed a submission deadline. Researchers scanning the literature through alerting services and database feeds will encounter the accepted manuscript under its permanent DOI, and the version-of-record record will inherit that visibility. The distinction between the two versions is maintained by the publisher’s labelling, but the scholarly community has, in effect, agreed to treat acceptance as the substantive gate. Peer review has already concluded; what remains is production craft rather than scientific judgement.

The production process behind that final version is worth appreciating, because it explains why the two-stage system exists at all. After acceptance, a manuscript enters author proofing, where the authors see the typeset article for the first time and are asked to verify corrections, check figure quality and confirm that nothing in the production process has distorted their meaning. Errors caught in an Article in Press are fixed at this stage, so that the Version of Record that ultimately replaces the early article is both typeset and corrected. The DOI’s persistence through this transition is what makes the process invisible to most readers: the URL they bookmarked, the citation they inserted into a manuscript, and the record in their reference manager all continue to resolve to the same paper, now in its final form.

Journals and authors also have a public-communication stake in the timing. Springer Nature, which publishes BMC Geriatrics, advises authors who are organising a press release for their Article in Press to contact their production editor as early as possible. The advice reflects a coordination problem: embargoes, journalist inquiries and institutional communications all depend on knowing when a paper will be publicly visible and in what form. If a research team wants media coverage to coincide with the earliest public appearance of their work, the production schedule has to accommodate it. Early access has therefore pushed publicity planning to the front of the publishing calendar, rather than leaving it until an issue date is fixed.

For readers, the practical guidance is straightforward. An Article in Press is a citable, permanent, peer-reviewed document, but it carries an explicit caveat: it is not the final Version of Record, and it may be edited further. Anyone quoting numbers, reproducing figures or building clinical recommendations on an early-access paper should be aware that the typeset version could differ in small but meaningful ways, and that corrections identified during production will appear in the final version under the same DOI. The labelling system exists precisely so that readers can make that judgement for themselves, and the support documentation that publishers maintain on Articles in Press explains the lifecycle in detail for authors and editors alike.

What emerges from all of this is a picture of scientific publishing in transition. The Article in Press stage compresses the distance between scientific acceptance and public availability to nearly zero, uses the DOI to guarantee that early citations never break, and preserves a clear, labelled distinction between the accepted manuscript and its polished final form. It is not glamorous — no new experiment is reported, no new hypothesis is tested — but it is infrastructure, and infrastructure determines how fast ideas travel. In a research landscape where the pace of publication is itself a competitive variable, the quiet machinery of early access may be doing as much for the speed of science as any single breakthrough it delivers.

Subject of Research: Early-access publishing of accepted manuscripts as Articles in Press with permanent DOIs

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, peer review, open access, Digital Object Identifier, BMC Geriatrics, Version of Record, scholarly publishing, author proofing, citation, production editing, early access, Springer Nature

An Article in Press is, by definition, a formally accepted, peer-reviewed manuscript that has not yet gone through the full copy-editing, typesetting, and author-proofing stages that produce the final Version of Record. The moment a manuscript is accepted, the journal assigns it a permanent Digital Object Identifier, or DOI, a unique alphanumeric string that acts as a persistent digital fingerprint for the paper. Because the DOI exists from the outset, researchers can view, share, and cite the work immediately, and any citation will continue to resolve correctly even after the final version replaces the early one.

The technical logic behind this system rests on the distinction between acceptance and publication. Traditional publishing models treated the printed journal issue as the definitive event, which meant that a paper accepted in, say, March might not appear in a citable form until the following calendar year. Electronic publishing dissolved that constraint. Once peer review confirms that a manuscript meets the journal’s scientific standards, the remaining steps are largely editorial and typographic rather than scientific, so there is no methodological reason to keep the findings hidden while fonts and page numbers are finalized.

That does not mean the early version is identical to what will eventually stand as the record. Springer Nature, which publishes BMC Pharmacology and Toxicology, notes that an Article in Press may be subject to further editing, because errors affecting the content can surface during final production. Copy editors may catch ambiguities in the abstract, inconsistencies in units or nomenclature, or formatting problems in tables and figures. Authors then review these changes during the proofing stage, and all corrections are folded into the final Version of Record. The early version is therefore a snapshot of the accepted science, not a guarantee of polished presentation.

To prevent confusion, the Article in Press is clearly labelled online to show that it is not the final Version of Record. Readers who land on the page see an explicit notice that the document is an early version and that the legal disclaimers applying to the journal remain in force. This labeling matters for scientific integrity: a clinician or regulator citing a toxicology result needs to know whether they are reading the definitive text or a version that could still be refined. The DOI, however, stays the same throughout, so the citation chain is never broken when the final version supersedes the early one.

For fully open access journals, this service is applied to every accepted manuscript, not just to selected papers. Open access publishing removes subscription barriers so that anyone, from a graduate student in a developing country to an industry toxicologist, can read the latest evidence without paying. Extending early access to all accepted papers in such journals amplifies that mission, because the interval between acceptance and the Version of Record can otherwise stretch to weeks or months depending on the production backlog. In fast-moving areas such as drug safety pharmacology, nanotoxicology, or the assessment of emerging contaminants, that interval can determine whether a new hazard is flagged before it causes harm.

The citation mechanics deserve a closer look, because they are the part most relevant to working scientists. A DOI is registered with the International DOI Foundation’s handle system, which redirects any query for that identifier to the publisher’s current landing page for the article. When the Article in Press is replaced by the Version of Record, the redirect target is updated, but the identifier itself never changes. Reference managers, indexing databases, and preprint aggregators that have already recorded the DOI therefore continue to point to the most authoritative version available. This is the same principle that underlies preprint servers, except that Articles in Press have already passed formal peer review, giving them a stronger evidentiary status than unreviewed preprints.

There are practical implications for authors as well. Journals encourage researchers who want to organize a press release for an Article in Press to contact their production editor as early as possible. Early coordination allows the press office to time publicity so that journalists receive the story while the paper is fresh, and it ensures that any embargo or messaging reflects the fact that the manuscript is still in production. For studies with potential public health relevance, such as a newly identified interaction between a common medication and a widely used supplement, early press engagement can accelerate the transfer of knowledge from the laboratory to the clinic and to the public.

The system also changes how the scientific community tracks emerging evidence. Literature searches that index Articles in Press surface findings months earlier than searches limited to final versions, which can influence the design of ongoing experiments. A research group planning an animal study on a particular compound, for example, may discover through an early-access paper that another team has already characterized a specific dose-response relationship, allowing them to refine their protocol or avoid redundant work. Systematic reviewers and meta-analysts, meanwhile, must simply be aware that the text they retrieve may still be subject to minor editorial revision, even though the underlying data and conclusions have been peer reviewed and accepted.

None of this alters the fundamental contract of scholarly publishing: peer review remains the gate, and the Version of Record remains the definitive, corrected, and formatted statement of the work. What the Article in Press model changes is timing. By decoupling the scientific verdict of peer review from the mechanical work of production, journals in pharmacology and toxicology can deliver vetted findings to the community at the speed modern research demands, while retaining the safeguards of labeling, correction, and a stable DOI that keep the scholarly record accurate and traceable. For a field in which the stakes are often measured in patient safety, that combination of speed and reliability is not a convenience but a structural advantage.

Subject of Research: Early-access publication of accepted peer-reviewed manuscripts as Articles in Press in pharmacology and toxicology journals

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, early access publishing, peer review, Digital Object Identifier, BMC Pharmacology and Toxicology, open access, Version of Record, scholarly publishing, citation, manuscript acceptance, Springer Nature, scientific communication

The DOI is the technical backbone of this arrangement. A Digital Object Identifier is a persistent alphanumeric string assigned to a scholarly work and registered with the DOI system, so that any citation pointing to the paper will resolve to the correct document even if the paper’s web location changes. Because an Article in Press receives its DOI at the early-access stage, that identifier does not change when the final version is later published. When the Version of Record appears, it simply replaces the Article in Press at the same DOI. For authors, this means citations accumulated during the early-access period carry forward seamlessly; for readers, it means a reference they have saved will always lead to the most current version of the work.

The speed advantage matters most in fields where findings age quickly. Geriatrics research, for example, often touches on clinical care questions whose answers influence practice decisions in hospitals, nursing homes and community health services. A study on fall prevention, dementia care or polypharmacy in older adults can inform guidelines and treatment planning, and every month of delay between acceptance and visibility represents time in which clinicians and other researchers are working without that evidence. Early access compresses that delay from months to days in many cases, allowing accepted findings to enter the scholarly conversation while they are still maximally useful.

It is important to understand what an Article in Press is and, just as crucially, what it is not. The version that appears online at this stage is the accepted manuscript: the text that has passed peer review and been approved by the journal’s editors. It is not yet the Version of Record, which is the fully typeset, copy-edited and proofed final article that appears in the journal’s official publication. To prevent any confusion, the Article in Press is clearly labelled online to show that it is not the final Version of Record, and all legal disclaimers relating to the journal apply to it. Readers, journalists and other researchers can therefore see at a glance the publication status of the document they are consulting.

Why does the accepted manuscript differ at all from the final published version? The answer lies in the production process that follows acceptance. After a paper is accepted, it moves into copy-editing and typesetting, where the manuscript is formatted to the journal’s layout, figures are processed to production standards, and the text is checked for consistency and clarity. During this final production process, errors affecting the content may be discovered, and an Article in Press may be subject to further editing as a result. Errors in the early-access version will be corrected during the author proofing stages of production, when authors review the typeset article and flag any problems before the final version is locked in.

This staged workflow creates a deliberate division of labour between speed and polish. Peer review, the most scientifically demanding gate, is completed before early access begins, so the substance of the work, its methods, data and conclusions, has already been vetted by independent experts and the handling editor. What remains at the Article in Press stage is largely presentation: typography, layout, reference formatting and the small factual corrections that surface when a manuscript is converted into a finished journal article. By publishing the vetted manuscript immediately and refining the presentation in parallel, the system avoids making readers wait for cosmetic work that does not affect the scientific validity of the findings.

Citation practice has adapted to accommodate this two-stage model. Because the early-access article carries a permanent DOI and can be formally cited, researchers referencing the work cite the Article in Press version, and that citation remains valid after the Version of Record replaces it. This is a meaningful improvement over older practices in which preprints or conference abstracts circulated without stable identifiers, making them difficult or impossible to cite reliably. In the modern system, the scholarly record is continuous: a paper becomes part of the citable literature at acceptance and stays continuously identifiable thereafter, with the DOI serving as the unbroken thread through every subsequent version.

Fully open access journals extend this service to every accepted manuscript, which has significant implications for the global reach of research. Open access publishing removes subscription barriers, meaning that an early-access article on older adult health can be read by clinicians, policymakers and researchers in any country the moment it appears, not only by readers at institutions with journal subscriptions. For research communities in low- and middle-income countries, where access to paywalled geriatrics literature has historically been limited, the combination of open access and immediate early-access publication means accepted evidence reaches its broadest possible audience without delay. It also accelerates secondary research, since systematic reviewers and meta-analysts can incorporate accepted findings sooner.

The system also has a communications dimension that authors are encouraged to use actively. Journals advise authors who are organising a press release for their Article in Press to contact their production editor as early as possible. Early coordination allows the journal’s communications team to align the press release with the article’s online appearance, ensuring that media coverage lands while the paper is fresh and that journalists are directed to the correct, citable version. For research with clear public relevance, such as studies on caregiving, frailty or health services for older populations, this early coordination can substantially amplify the attention a paper receives.

For readers evaluating an Article in Press, the practical guidance is straightforward. The scientific content has been peer reviewed and accepted, so the findings can be treated as part of the literature and cited with confidence using the DOI. At the same time, readers should remain aware that wording, figures and minor details may change slightly in the final Version of Record as author proofing and production corrections are completed. The early-access label exists precisely so that this status is never in doubt. As scholarly publishing continues to move toward faster, more open models, the Article in Press stage represents a widely adopted compromise: science becomes visible and citable as soon as it has earned that status through peer review, while the machinery of professional production continues to refine the final, permanent record behind the same stable identifier.

Subject of Research: Early-access publishing of accepted peer-reviewed manuscripts as Articles in Press with permanent DOIs

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, peer review, DOI, open access, scholarly publishing, BMC Geriatrics, Version of Record, early access, manuscript acceptance, citation, Springer Nature, scientific publishing

The Article in Press model rests on a simple but consequential premise: the intellectual content of a paper has already been validated by peer review, so the remaining work is largely technical. Copyediting, typesetting, reference linking, and author proofing are production tasks rather than scientific ones. By releasing the accepted manuscript before those tasks are complete, publishers ensure that a discovery enters the public record at the earliest defensible moment. Each Article in Press receives its DOI at this early stage, and that identifier is permanent. When the final Version of Record is later published, it replaces the early-access version while retaining the same DOI, so every citation made in the interim remains valid. This continuity of identifier is what makes the system workable, because citation stability is the backbone of the scholarly record.

For pharmacology and toxicology, where findings can influence drug development pipelines, regulatory submissions, and clinical practice, the speed advantage is more than a matter of convenience. A study reporting an unexpected adverse effect, a novel mechanism of drug action, or a promising preclinical result may be relevant to other laboratories within days of acceptance. Under a traditional publication schedule, that relevance could be delayed by production timelines measured in months. Early access compresses the interval between acceptance and visibility, allowing competing teams to replicate findings, clinicians to weigh emerging evidence, and systematic reviewers to incorporate the most current data. In fields where replication and rapid synthesis of evidence are essential, the difference between weeks and months can shape the trajectory of an entire research area.

The system is not without caveats, and publishers are careful to flag them. An Article in Press is clearly labelled online to indicate that it is not the final Version of Record. The reason is practical rather than cosmetic: errors affecting the content may still be discovered during the final production process. Typesetting can introduce mistakes, references can be mislinked, figures can be rendered incorrectly, and authors themselves frequently catch residual problems during the proofing stage. Corrections made during author proofing are applied to the final Version of Record, not retroactively propagated to every copy of the early-access file that may have been downloaded or cached. Readers who rely on an Article in Press are therefore consulting a version that is scientifically vetted but editorially provisional, a distinction that matters most for numerical data, author lists, and funding statements.

Because of that provisionality, the Article in Press stage also interacts with the correction machinery of scholarly publishing. If a substantive error is identified after acceptance but before final publication, it can be corrected without the formal apparatus of a post-publication correction notice, since the Version of Record has not yet been issued. This gives authors and production teams a built-in window for quality control that did not exist under older print-driven workflows. Once the final version appears, the same DOI persists, and any subsequent corrections follow the journal’s standard correction policies. In effect, the early-access period functions as an extended proofing phase conducted in public view, with the safeguard that the labelled status of the document tells readers exactly how much editorial refinement has taken place.

Open access journals have embraced this model most fully. Springer Nature notes that fully open access journals provide the Article in Press service on every accepted manuscript, meaning that no accepted paper waits behind a production backlog before becoming citable. The alignment between open access and early access is natural: both philosophies prioritize the rapid, unrestricted dissemination of research findings. For authors, this means that the moment of acceptance effectively becomes the moment of publication in the eyes of many indexing services and institutional reporting systems. For funders who mandate immediate open availability of supported research, the early-access DOI provides a concrete, citable artifact that satisfies compliance requirements without waiting for issue assignment.

The mechanics of citation during the early-access period deserve particular attention, because they illustrate how the scholarly record maintains coherence across versions. When a researcher cites an Article in Press, the citation points to the DOI rather than to a volume, issue, or page number, none of which exist yet. Reference managers and bibliographic databases handle these citations by resolving the DOI, which always leads to the current authoritative version of the document. Once the Version of Record replaces the early-access file, the same resolution path delivers the final, typeset article. This design eliminates the broken citations and duplicate records that plagued early attempts at online-first publishing in the late 1990s and early 2000s, when provisional articles sometimes accumulated parallel citation histories that diverged from their final versions.

There is also a communications dimension to the model. Springer Nature encourages authors who wish to organize a press release for their Article in Press to contact their production editor as early as possible in the process. Early coordination matters because science journalists often work on tight timelines, and embargoes, interviews, and multimedia assets are easier to arrange when the publication date is known well in advance. For high-profile pharmacological findings, such as a new compound with therapeutic potential or a safety signal with public health relevance, the ability to plan coverage around an early-access date rather than a distant issue date can determine whether a study captures public attention or slips past unnoticed. The production editor serves as the coordination point, aligning the technical publication schedule with the communications plan.

From the reader’s perspective, the practical guidance is straightforward. An Article in Press can be read, shared, and cited with confidence in its scientific conclusions, because peer review has already been completed. However, users should note the label, quote figures and author affiliations with the awareness that minor corrections may still occur, and revisit the DOI if absolute certainty about wording or data presentation is required. Legal disclaimers applying to the journal apply equally to the early-access version, so the usual cautions about interpreting preliminary findings, particularly in pharmacology and toxicology where translational implications are often drawn cautiously, remain in force. The early-access label is not a warning against use; it is an honest description of the document’s position within the production pipeline.

Taken together, the Article in Press system represents a pragmatic compromise between two competing ideals of scientific publishing: the desire for absolute editorial polish and the desire for immediate dissemination of validated knowledge. By assigning a permanent DOI at acceptance, labelling the provisional status of the document, correcting errors during proofing, and replacing the early version with a final Version of Record under the same identifier, publishers have built a pipeline that preserves the integrity of the citation record while dramatically shortening the wait for new findings. For researchers in pharmacology and toxicology, and for the journalists and clinicians who translate their work, the model means that the most current evidence is increasingly available at the moment it is scientifically ready, not merely when the printing schedule allows. As open access continues to expand across the biomedical literature, the expectation that acceptance and public availability should coincide is likely to become the norm rather than the exception.

Subject of Research: Early-access publication of accepted peer-reviewed manuscripts as Articles in Press with permanent DOIs

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, early access publishing, peer review, Digital Object Identifier, open access, Springer Nature, BMC Pharmacology and Toxicology, Version of Record, scholarly publishing, citation stability, author proofing, scientific communication

An Article in Press is, by definition, the accepted manuscript of a paper that has survived formal peer review but has not yet completed the production process that yields the final Version of Record. The moment a journal formally accepts a submission, the publisher can post this accepted version online under a permanent Digital Object Identifier, the DOI that serves as the paper’s unchanging address in the scholarly record. Because the DOI is assigned at this early stage, the article can immediately be viewed, shared, and cited by other researchers. In fast-moving fields, and in geriatrics where demographic pressures are driving urgent questions about dementia care, frailty, polypharmacy, and the organisation of health systems for older adults, that head start matters. A finding that might otherwise sit in an editorial queue for months can begin informing systematic reviews, meta-analyses, and clinical guideline committees while the typesetters are still at work.

The technical logic of the system rests on the distinction between two versions of the same paper. The Article in Press is the author’s accepted manuscript, typically the text as approved by the editors and peer reviewers, formatted in a standard template rather than in the journal’s final layout. The Version of Record is the fully produced article that emerges after copyediting, typesetting, author proofing, and the resolution of any remaining queries. Crucially, when the Version of Record is published, it replaces the Article in Press online while retaining the same DOI. This is the elegant part of the design: the citation, the link, and the usage statistics all carry over seamlessly. A researcher who cited the early version in June finds that the same DOI now resolves to the polished final article in September. Nothing in the scholarly record breaks, and no duplicate records accumulate.

That continuity, however, comes with an important caveat that publishers make explicit. An Article in Press may be subject to further editing, because errors affecting the content can be discovered during the final production process. The production stage is where a manuscript meets professional copyeditors who check references, units, statistical notation, figure labels, and the thousand small details that peer reviewers, focused on the science itself, are not always tasked with catching. Errors found at this stage are corrected during the author proofing stages, in which the authors review the typeset version line by line and approve or amend the changes. All of these corrections are reflected in the final Version of Record. In other words, the early version is a genuine, citable scientific document, but it is not guaranteed to be error-free in the way the final article is expected to be.

To protect readers from mistaking one for the other, publishers label the Article in Press clearly online, signalling that it is not the final Version of Record. This labelling is not a formality. It carries legal weight as well, since all the disclaimers that apply to the journal apply to the early version too. For readers in applied fields, the practical implication is straightforward: when an early-access paper reports a clinical finding, it is reasonable to read it, cite it, and discuss it, but careful readers will check whether the Version of Record has since appeared and whether any corrections were introduced along the way. The DOI system makes that check easy, because following the same identifier always leads to the most current published form of the work.

The model is closely tied to the economics of open access publishing. Fully open access journals, which fund their operations through article processing charges rather than subscription paywalls, provide the Article in Press service on every accepted manuscript. This universal application reflects a broader philosophical commitment: if the public and the research community are paying for immediate, unrestricted access to findings, there is little justification for delaying that access through a lengthy production pipeline. In geriatrics, where much of the relevant evidence is produced by publicly funded research and consumed by publicly funded health services, the alignment between open access principles and early-access mechanics is particularly consequential. A hospital geriatrician, a nursing home medical director, or a policy analyst drafting guidance on falls prevention can all read the same accepted manuscript on the same day it is posted, with no subscription required.

The early-access model also changes the rhythm of scientific communication itself. Under the traditional system, the formal publication date functioned as the single moment at which a study entered the citable literature, and press offices timed their announcements to that date. Under the current system, the citable life of a paper begins at acceptance, which means that the diffusion of a finding through the community starts earlier and unfolds more gradually. Journals actively encourage authors to think about this window: guidance for authors preparing press releases about an Article in Press advises them to contact their production editor as early as possible, so that publicity, media coverage, and the final publication can be coordinated rather than left to chance. For a study with direct implications for the care of older people, that coordination can determine whether the finding reaches practitioners in a timely, well-contextualised way or arrives as a fragment of a headline detached from its caveats.

For the scientists doing the work, the system offers both opportunity and responsibility. The opportunity is speed: a doctoral candidate whose trial of a rehabilitation intervention in older adults has just been accepted can see the work enter the literature immediately, which matters for grant reporting, career progression, and, most importantly, for other teams building on the result. The responsibility lies in the proofing stage. Because the Article in Press will be replaced by the Version of Record, the author proofs are the last reliable checkpoint at which substantive errors can be caught. A mislabelled figure, a transposed risk ratio, or an incorrect dosage in a methods section that slips through the proofs becomes part of the permanent record, correctable only through a formal correction notice later. The system therefore places a premium on authors treating the proofing stage with the same seriousness they brought to the peer review itself.

For readers and journalists, a few habits make navigating early-access literature safer. First, note the label: if a page identifies an article as an Article in Press, treat its details as potentially subject to change. Second, cite the DOI rather than a screenshot or a PDF copy, since the DOI is the thread that connects the early version to the final one. Third, when a finding is important enough to act on, whether in a clinic, a care home, or a news story, check whether the Version of Record has appeared and read that version, because it represents the publisher’s and authors’ final approved text. None of this diminishes the value of the early version; it simply acknowledges that the accepted manuscript and the finished article are two stages of a single process, each with its own degree of polish.

The larger story is one of a publishing ecosystem adapting to the tempo of modern science. The Article in Press model, now standard across fully open access journals, decouples the moment of scientific acceptance from the moment of final production, letting the two proceed on their own appropriate timelines while a permanent identifier keeps them bound together. In geriatrics, a field racing to generate usable evidence for the fastest-ageing populations in history, that decoupling is not an administrative curiosity but a practical accelerant. The accepted finding reaches the community sooner; the finished, corrected, typeset article follows when it is ready; and the DOI ensures that no reader, at any point in that interval, loses track of where the work lives. It is a quiet piece of infrastructure, but it is one of the reasons that evidence about the health of older adults moves from laboratory and clinic into the global literature faster today than at any previous point in the history of the field.

Subject of Research: The Article in Press early-access publishing model and its implications for open access geriatrics research

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Article in Press, open access, peer review, DOI, BMC Geriatrics, Version of Record, scholarly publishing, early access, geriatrics, manuscript acceptance, author proofing, scientific communication

The technical foundation of the Article in Press system rests on the DOI, a persistent alphanumeric identifier assigned to a digital object that resolves through the DOI registry to a stable landing page. Because the DOI is assigned at the point of acceptance rather than at final publication, the early version of the paper acquires a citable identity from the very first day it appears online. Other researchers can reference the work in their own manuscripts, grant applications, and preprint discussions without waiting for the Version of Record. When the final, copy-edited and typeset version is later published, it replaces the Article in Press version while retaining exactly the same DOI, which means that every citation made in the interim continues to resolve correctly. This continuity of identifier is what makes early access compatible with the citation infrastructure that underpins modern scholarly communication.

Speed matters in science for reasons that go well beyond professional impatience. In fast-developing fields such as pharmacology and toxicology, where new drug candidates, emerging contaminants, and novel therapeutic targets are constantly under investigation, a delay of several months between acceptance and formal publication can mean the difference between a finding that shapes the next experiment and one that is scooped or rendered redundant. Early access allows laboratory groups to build on accepted results immediately, funding agencies to consider the newest evidence in their assessments, and clinicians in applied fields to see relevant toxicological data without waiting for a journal issue to close. For authors, the early appearance of a citable, DOI-bearing version also establishes priority in a landscape where preprint servers have made rapid disclosure the norm.

It is important to understand that an Article in Press is not an unreviewed or provisional scientific document. It is, by definition, an accepted manuscript, meaning it has already passed through the journal’s peer-review process and been approved for publication by the editors. What distinguishes it from the final Version of Record is the stage of production it has reached. The accepted manuscript may not yet reflect the full copy-editing, typesetting, and proofing work that transforms a submission into a polished journal article. Publishers make this status explicit by clearly labelling the document online, so that readers understand they are looking at an early version rather than the definitive record. All of the legal disclaimers that apply to the journal apply equally to the early version, preserving the same standards of accountability.

The production stage that follows acceptance is more than cosmetic, and publishers are candid about the possibility of change. According to the guidance accompanying journals that use this model, an Article in Press may be subject to further editing, because errors affecting the content can be discovered during the final production process. Errors identified in the early version are corrected during the author proofing stages, in which authors review the typeset article and flag discrepancies before the Version of Record is finalized. Corrections made at this stage are reflected in the final published version. This workflow acknowledges a practical reality of publishing: even after peer review, the mechanical and editorial processes of production can surface mistakes in figures, references, units, or wording that need to be fixed before the scientific record is considered complete.

For fully open access journals, the early-access service is offered on every accepted manuscript, making it a standard feature of the publication pipeline rather than an occasional privilege. This universality has significant implications for equity in science. Researchers at institutions with limited journal subscriptions, as well as practitioners and policymakers outside academia, can read accepted findings at the moment they become available, provided the journal is open access. In fields such as pharmacology and toxicology, where regulators, clinicians, and public health authorities all draw on the primary literature, the immediate availability of accepted manuscripts can accelerate the translation of research into practice. The open access model and the early access model are thus complementary: one removes the paywall, and the other removes the waiting period.

The rise of Articles in Press also intersects with the broader cultural shift toward preprints, the manuscripts that scientists post on community servers before peer review. Preprints maximize speed but carry no guarantee of quality control, while Articles in Press occupy a middle ground: they are slower than preprints but carry the imprimatur of formal acceptance and peer review. For many readers, this makes the Article in Press a uniquely trustworthy signal, combining the timeliness of early disclosure with the assurance that experts in the field have already scrutinized the methods and conclusions. Journals and publishers have increasingly emphasized this distinction in their communications, encouraging authors to share their accepted work widely while making clear that the definitive, proofed version will follow.

Authors preparing to publish under this model are also given practical guidance about visibility. Publishers advise researchers who wish to organize a press release around their Article in Press to contact their production editor as early as possible in the process. Early coordination matters because press outreach, institutional communications, and media embargoes all depend on knowing when the citable version will appear online. For high-profile findings, particularly those with clinical or public safety implications, the difference between a press release issued on the day of acceptance and one issued weeks later can determine how quickly the wider public and professional communities learn of the work. The guidance reflects an understanding that dissemination is now part of the publication workflow, not an afterthought.

Behind the scenes, the transition from Article in Press to Version of Record is managed so that the scholarly record remains coherent. The early version is hosted under the same DOI that will persist for the life of the article, and when the final version is published it simply replaces the early version at that identifier. Readers who bookmarked the article, cited it in reference managers, or linked to it from other papers will find the definitive version when they follow the same DOI. This design eliminates the broken links and duplicate records that plagued earlier eras of electronic publishing, when accepted manuscripts, preprints, and final versions sometimes circulated under different identifiers with no formal connection between them. The DOI, in effect, serves as the thread of continuity that ties the whole lifecycle of a paper together.

As scientific publishing continues to evolve, the Article in Press model illustrates a broader principle: the infrastructure of scholarly communication is being redesigned around immediacy without sacrificing rigor. Peer review still gates entry into the literature, production still polishes the final product, and the Version of Record still serves as the definitive citation of choice. But the long, silent interval between acceptance and publication, once an unavoidable feature of print-era workflows, has been compressed into a brief transitional phase that is transparent, labelled, and citable. For researchers in pharmacology, toxicology, and every other discipline served by this model, the message is straightforward: once your work is accepted, it is already part of the conversation, and the world can start reading it the same day.

Subject of Research: Early-access publishing of accepted peer-reviewed manuscripts as Articles in Press with persistent DOIs

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, peer review, DOI, open access, scholarly publishing, Version of Record, Springer Nature, BMC Pharmacology and Toxicology, early access, scientific communication, manuscript acceptance, citation

The core idea behind the Article in Press is deceptively simple. Once a paper has cleared peer review and been formally accepted by a journal’s editors, the publisher makes the accepted manuscript available online in a clearly labelled early form. This version is not a rough draft and not a preprint that has bypassed review; it is a post-review document that has already survived the scrutiny of editors and referees. What distinguishes it from the final Version of Record is the production work that still lies ahead: typesetting, copy-editing, author proofing, and the composition of the final paginated layout. By releasing the accepted manuscript at this stage, publishers compress the delay between discovery and dissemination, a delay that in the print era could stretch to months.

A central feature of the Article in Press is its permanent Digital Object Identifier, or DOI. The DOI is a persistent alphanumeric string that resolves to the paper’s location on the publisher’s platform regardless of where the article sits in its production journey. Crucially, when the final Version of Record is published, it replaces the Article in Press while retaining the same DOI. This design means that citations made against the early version do not break or point to a dead end; they simply resolve to the most current, authoritative form of the paper. For a fast-moving field such as geriatrics, where findings about ageing, frailty, and chronic disease management can influence clinical practice, the stability of the DOI chain is more than a technical nicety. It allows clinicians, guideline committees, and other researchers to cite emerging evidence with confidence, knowing the reference will remain valid.

The early-access model also carries an important caveat that publishers state explicitly: an Article in Press may be subject to further editing. Errors affecting the content can be discovered during the final production process, and mistakes present in the early version will be corrected during the author proofing stages. Corrections are then reflected in the final Version of Record. This is a deliberate transparency measure rather than a weakness hidden from readers. The Article in Press is clearly labelled online to show that it is not the final Version of Record, and all legal disclaimers relating to the journal apply to it. In effect, the publisher draws a visible boundary around the document, telling the reader: the science here has been peer reviewed and accepted, but the polished, fully proofed text is still in production.

For science journalists and press officers, this distinction matters enormously. A finding reported from an Article in Press is real, peer-reviewed science, but specific numbers, phrasings, or even tables could shift slightly before the Version of Record appears. Springer Nature’s guidance encourages authors who are organising a press release for their Article in Press to contact their production editor as early as possible, precisely so that publicity and production can be coordinated. A press release issued while the paper is still in proof can be timed to coincide with the final publication, ensuring that media coverage points readers to the definitive version. When that coordination fails, news stories can end up describing details that were subsequently corrected, an outcome that erodes trust in both journalism and the underlying research.

The rise of early-access publishing reflects a broader transformation in how scientific knowledge circulates. In the traditional subscription model, a paper’s public life often began only when it was assigned to a journal issue, sometimes many months after acceptance. The open-access movement, in which the cost of publication is borne upfront and readers worldwide can access the work without a paywall, has pushed publishers to remove every unnecessary delay. Fully open-access journals now provide the Article in Press service on every accepted manuscript, so the moment a paper is accepted it becomes part of the citable record. For fields such as geriatric medicine, where the global burden of age-related disease is rising and evidence can inform policy on pensions, caregiving, and public health, this acceleration has practical consequences: a trial result or cohort analysis can reach clinicians and policymakers weeks or months earlier than under the old timetable.

From a technical standpoint, the versioning system underlying Articles in Press resembles a controlled chain of custody for a document. The accepted manuscript enters production, where professional copy-editors check formatting, references, and figures, and where authors review proofs and flag errors. Each correction is folded into the next version, and the final Version of Record supersedes the early version at the same DOI. This is different from the preprint culture familiar from physics and biology servers, where unreviewed manuscripts accumulate community feedback and may never be formally published. The Article in Press sits between these worlds: it is post-review but pre-production, citable but provisional. Readers who encounter one online can verify its status from the label, which functions as a quality signal and a warning at the same time.

There are also implications for how the scientific record is measured and audited. Because the Article in Press and the Version of Record share a DOI, citation databases and reference managers treat them as a single entity, consolidating the paper’s scholarly impact rather than splitting it across two records. This consolidation benefits authors, whose work begins accruing citations immediately, and it benefits bibliometric analyses, which no longer need to reconcile duplicate records. At the same time, the possibility of post-acceptance corrections underscores why readers should always consult the latest version of a paper when drawing on its findings. Publishers maintain version histories on their platforms, so a diligent reader can trace what changed between the early version and the final one, a level of transparency that was largely impossible in the print-only era.

For the research community in geriatrics and beyond, the practical advice that follows from this system is straightforward. Authors should treat acceptance not as the end of the publication process but as the beginning of its final phase, responding promptly to proofing queries and coordinating with production editors if press activity is planned. Journalists should check whether a paper they are covering is an Article in Press and, if so, note that the Version of Record may refine the details. Readers should look for the early-access label and understand that it signals peer-reviewed, accepted science that is still being polished. None of these caveats diminish the value of early access; they simply define its proper use. The Article in Press represents a pragmatic compromise between two legitimate demands: the scientific community’s need to share verified findings quickly, and the publishing system’s obligation to deliver accurate, corrected, and professionally produced documents. As open access continues to expand, this once-obscure production stage has become a visible and consequential part of how the world learns about new research.

Subject of Research: Early-access scientific publishing and the Article in Press workflow in open-access journals

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Article in Press, open access, peer review, DOI, Version of Record, scientific publishing, Springer Nature, BMC Geriatrics, early access, manuscript production, citation, scholarly communication

An Article in Press is an early-access version of the accepted, peer-reviewed manuscript. It is not a preprint in the informal sense: it has passed editorial assessment and external peer review, and it carries a permanent Digital Object Identifier, or DOI. That DOI is the crucial technical detail. Because the identifier is assigned at the Article in Press stage and retained when the final version is published, any citation made to the early version remains valid indefinitely. Researchers can view, share, and cite the work immediately, and the citation will continue to resolve correctly after the finished Version of Record replaces the preliminary text.

The system exists because producing a final journal article involves more than acceptance. After peer review concludes, the manuscript moves into copyediting, typesetting, and author proofing. During these stages, errors affecting the content may be discovered, and the Article in Press may be subject to further editing. Errors found in the early version are corrected during the author proofing stages of production, and those corrections are reflected in the final Version of Record. In other words, the early version is a snapshot of the accepted science, while the Version of Record is the fully refined, publisher-formatted article.

Transparency is a central feature of the model. An Article in Press is clearly labelled online to show that it is not the final Version of Record. This labelling protects readers by making the status of the document unambiguous: anyone encountering the paper knows they are looking at an accepted manuscript that may still undergo minor changes. All legal disclaimers relating to the journal apply to the early version just as they do to the final one, so the same ethical and legal framework governs both stages of publication.

When the final Version of Record is published, it replaces the Article in Press while retaining the same DOI. This continuity matters for the scholarly record. Citation counts, reference links, and database indexing all attach to the DOI rather than to a particular rendering of the text. Because the identifier never changes, the transition from early version to final version is seamless for readers, libraries, and indexing services. Nothing in the citation chain breaks, and no duplicate records accumulate under different identifiers.

The model is closely tied to open access publishing. Fully open access journals provide this service on every accepted manuscript, meaning that no accepted paper waits in a production queue before becoming publicly visible. For pharmacology and toxicology research, where findings can inform drug safety decisions, clinical practice, and regulatory thinking, the speed advantage is significant. A study on a drug interaction or a toxicological mechanism can be read and cited by other researchers the moment it is accepted, rather than weeks later.

For authors, the Article in Press stage also offers a practical communications opportunity. Researchers who wish to organise a press release for their accepted paper are advised to contact their production editor as early as possible. Early coordination allows institutional press offices and journal production teams to align their timelines, so that media coverage can coincide with the paper becoming publicly available rather than trailing behind it by several weeks.

The distinction between an Article in Press and other forms of early sharing is worth understanding. Preprints, posted on servers before peer review, communicate findings quickly but carry no guarantee of quality control. Articles in Press occupy a different position: peer review is complete, the journal has accepted the work, and a permanent DOI exists, yet final copyediting and proofing remain outstanding. For readers weighing the reliability of a new paper, that status label is a meaningful signal about how far the manuscript has travelled through the publication pipeline.

Springernature, the publisher behind the BMC journal portfolio, maintains public documentation explaining the Article in Press process through its support resources. Authors and readers who want more detail about how early-access versions are handled, corrected, and ultimately replaced can consult these guides directly. The documentation reinforces the core promise of the system: that early visibility never comes at the cost of a stable, permanent scholarly record.

As scientific publishing continues to accelerate, the Article in Press model illustrates how journals balance two competing demands: the community’s desire for immediate access to new findings, and the need for careful, error-free final versions. By publishing accepted manuscripts immediately under a permanent DOI, labelling them clearly as preliminary, and correcting any errors discovered during production before the Version of Record appears, journals such as BMC Pharmacology and Toxicology offer researchers the best of both worlds. The science reaches its audience faster, and the permanent record remains as reliable as ever.

Subject of Research: The Article in Press early-access publishing model for accepted peer-reviewed manuscripts

Article Title: Articles in Press

Article References: Articles in Press. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Articles in Press, BMC Pharmacology and Toxicology, peer review, DOI, Version of Record, open access, early access publishing, scholarly publishing, manuscript acceptance, Springer Nature, author proofing, citation